Magenta Therapeutics is using the curative power of stem cell transplants to treat patients with genetic and autoimmune diseases. Stem cell transplants involve three main steps: (i) mobilization and collection of stem cells from patients’ bone marrow, (ii) conditioning, to remove patients’ stem cells to make space for new ones and (iii) transplantation and engraftment of healthy stem cells to restore the immune and blood system free of disease. Magenta is developing programs to enhance the first two steps of stem cell mobilization involving small molecule and antibody-drug conjugate identification. Clinical progress has been made with MGTA-145 to mobilize and collect stem cells in multiple myeloma patients.

<p>Magenta Therapeutics is using the curative power of stem cell transplants to treat patients with genetic and autoimmune diseases. Stem cell transplants involve three main steps: (i) mobilization and collection of stem cells from patients’ bone marrow, (ii) conditioning, to remove patients’ stem cells to make space for new ones and (iii) transplantation and engraftment of healthy stem cells to restore the immune and blood system free of disease. Magenta is developing programs to enhance the first two steps of stem cell mobilization involving small molecule and antibody-drug conjugate identification. Clinical progress has been made with MGTA-145 to mobilize and collect stem cells in multiple myeloma patients.</p>


Magenta Therapeutics

Founded: 2016
Location: Cambridge, MA
Employee range: 50 - 200
Funding: $100M IPO Jun 2018

Short description:

Drug notes:

Long description:

Jobs: